- Home
- ACAD vs ATAT Comparison
ACAD vs ATAT Comparison
Compare ACAD & ATAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- ATAT
- Stock Information
- Founded
- ACAD 1993
- ATAT 2013
- Country
- ACAD United States
- ATAT China
- Employees
- ACAD N/A
- ATAT N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- ATAT Hotels/Resorts
- Sector
- ACAD Health Care
- ATAT Consumer Discretionary
- Exchange
- ACAD Nasdaq
- ATAT Nasdaq
- Market Cap
- ACAD 3.8B
- ATAT 4.2B
- IPO Year
- ACAD 2004
- ATAT 2022
- Fundamental
- Price
- ACAD $20.98
- ATAT $35.37
- Analyst Decision
- ACAD Buy
- ATAT Strong Buy
- Analyst Count
- ACAD 18
- ATAT 2
- Target Price
- ACAD $27.71
- ATAT $37.40
- AVG Volume (30 Days)
- ACAD 2.1M
- ATAT 1.6M
- Earning Date
- ACAD 08-05-2025
- ATAT 08-28-2025
- Dividend Yield
- ACAD N/A
- ATAT 1.25%
- EPS Growth
- ACAD N/A
- ATAT 28.10
- EPS
- ACAD 1.37
- ATAT 1.25
- Revenue
- ACAD $996,283,000.00
- ATAT $1,059,112,934.00
- Revenue This Year
- ACAD $13.39
- ATAT $31.42
- Revenue Next Year
- ACAD $10.59
- ATAT $21.88
- P/E Ratio
- ACAD $15.33
- ATAT $28.41
- Revenue Growth
- ACAD 22.42
- ATAT 43.38
- 52 Week Low
- ACAD $13.40
- ATAT $15.22
- 52 Week High
- ACAD $25.23
- ATAT $37.46
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- ATAT 66.11
- Support Level
- ACAD $20.75
- ATAT $35.05
- Resistance Level
- ACAD $23.09
- ATAT $37.46
- Average True Range (ATR)
- ACAD 0.78
- ATAT 1.23
- MACD
- ACAD -0.20
- ATAT 0.26
- Stochastic Oscillator
- ACAD 9.83
- ATAT 68.10
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.